Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis
暂无分享,去创建一个
K. Kozak | M. Amneus | Suzanne M Pusey | Feng Su | M. Luong | Sam A Luong | S. Reddy | R. Farias-Eisner | Katherine R Kozak
[1] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983 .
[2] Jacques Estève,et al. Trends in cancer incidence and mortality. , 2009 .
[3] B. Karlan,et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. , 1994, Gynecologic oncology.
[4] S. Barnhill,et al. CA 125: The past and the Future , 1998, The International journal of biological markers.
[5] M Markman,et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.
[6] G. Wright,et al. Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.
[7] Z. Ye,et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Merchant,et al. A rapid protein profiling system that speeds study of cancer and other diseases. , 2000, American clinical laboratory.
[9] Ann-Marie Martoglio,et al. Changes in Tumorigenesis- and Angiogenesis-related Gene Transcript Abundance Profiles in Ovarian Cancer Detected by Tailored High Density cDNA Arrays , 2000, Molecular medicine.
[10] U Menon,et al. Recent developments in ovarian cancer screening , 2000, Current opinion in obstetrics & gynecology.
[11] D R Schwartz,et al. Coordinately up-regulated genes in ovarian cancer. , 2001, Cancer research.
[12] G. Wright,et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.
[13] D. Lockhart,et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] S. Mok,et al. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. , 2001, BioTechniques.
[15] R. Berkowitz,et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.
[16] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[17] K. Zatloukal,et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis , 2001, Proteomics.
[18] G. Mills,et al. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. , 2001, Journal of the National Cancer Institute.
[19] D. Scudiero,et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. , 2001, The American journal of pathology.
[20] D. Fishman,et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. , 2001, Gynecologic oncology.
[21] R. Bast,et al. OVX1, macrophage‐colony stimulating factor, and CA‐125‐II as tumor markers for epithelial ovarian carcinoma , 2001, Cancer.
[22] E. Fung,et al. Protein biochips for differential profiling. , 2001, Current opinion in biotechnology.
[23] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[24] David I. Smith. Transcriptional profiling develops molecular signatures for ovarian tumors. , 2002, Cytometry.
[25] Enrique A Dalmasso,et al. Current achievements using ProteinChip Array technology. , 2002, Current opinion in chemical biology.
[26] D. Chan,et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.
[27] G. Mills,et al. Early detection of ovarian cancer: promise and reality. , 2002, Cancer treatment and research.
[28] E. Kohn,et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer , 2002, Proteomics.
[29] D. Fishman,et al. The scientific basis of early detection of epithelial ovarian cancer: the National Ovarian Cancer Early Detection Program (NOCEDP). , 2002, Cancer treatment and research.
[30] Terukazu Nakamura,et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. , 2002, Cancer research.
[31] R. Berkowitz,et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.
[32] C. Pilarsky,et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. , 2002, The American journal of pathology.
[33] D. Mutch. Surgical management of ovarian cancer. , 2002, Seminars in oncology.
[34] B. Shan,et al. Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer. , 2002, Gynecologic oncology.
[35] A. van Dalen,et al. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma , 2002, Cancer.
[36] A. Mills,et al. Gene expression profiling diagnosis through DNA molecular computation. , 2002, Trends in biotechnology.
[37] Thomas P Conrads,et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.
[38] Bjarte Dysvik,et al. Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles , 2002, International journal of cancer.
[39] E. Fung,et al. Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.
[40] D. Atallah,et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[42] D. Katsaros,et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Ignace Vergote,et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. , 2003, Cancer research.
[44] D. Katsaros,et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. , 2003, Cancer research.
[45] J. Welsh,et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum , 2003, Proceedings of the National Academy of Sciences of the United States of America.